BioMarin (BMRN) Stock Looks To Trade At A Discount To Fair Value

BioMarin Pharmaceutical stock has delivered a loss of about 30.5% over the past three years, yet the valuation checks currently frame it as looking inexpensive on several fronts. For investors, that gap between weaker long term returns and stronger value signals raises questions about how the market is weighing BioMarin today.

• Over the past 3 years, BioMarin Pharmaceutical is down about 30.5%, which points to a long stretch of underwhelming shareholder returns despite more recent gains.
• The agreed deal to acquire Alesta Therapeutics, focused on an oral therapy candidate for hypophosphatasia, can support long term revenue potential, while integration and development risks may influence how much value ultimately flows through to shareholders.
• On the broader checks, BioMarin Pharmaceutical screens on the cheap side, with a high value score that indicates the stock looks undervalued across several valuation measures.

The issue now is whether BioMarin Pharmaceutical’s current price already reflects the risks around execution and drug development, or if the recent underperformance has left investors with a margin of safety.

Spot undervalued opportunities beyond BioMarin Pharmaceutical by comparing it with a curated group of 45 high quality undervalued stocks.

Is BioMarin Pharmaceutical Still Cheap on Sales?

P/S is a useful way to look at BioMarin Pharmaceutical because revenue is a key reference point for a company that is still heavily investing in its pipeline.

BioMarin Pharmaceutical currently trades on a P/S ratio of about 3.7x. That is well below the biotechs industry average of around 13.2x and also below the peer group average of roughly 14.4x. Based on the valuation model that blends the company’s growth profile, margins, size and risk, a fair P/S ratio is estimated at about 4.9x, which remains higher than where the stock trades today.

Despite the recent Alesta Therapeutics deal lifting interest in BioMarin Pharmaceutical, the current P/S still points to a discount relative to what this framework suggests as a reasonable range. The gap between the present multiple and the indicated fair ratio suggests the stock price is not fully reflecting the sales base that investors are paying for.

On the P/S multiple, BioMarin Pharmaceutical stock appears undervalued compared with both its industry and this fair value framework.

See what the numbers say about this price — find out in our valuation breakdown.

The BioMarin Pharmaceutical Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for BioMarin Pharmaceutical pick up where this valuation puzzle leaves off, by spelling out what growth, margin and earnings paths would need to play out for the stock to be worth materially more or less than today’s price. Rather than relying on a single multiple or model, each Narrative lays out its own set of assumptions behind a fair value view so you can compare those against BioMarin Pharmaceutical's actual results over time. Narratives sit on Simply Wall St’s Community page and are designed to help you see what is implicitly baked into the current share price before you decide how to interpret it.

Community views on BioMarin Pharmaceutical are sharply split, with one side focused on upside from rare disease assets and the other on pricing and concentration risks.

Bull case: 48% undervalued

"BioMarin's next-generation pipeline, led by the potential best-in-class long-acting CNP candidate BMN 333, is poised not just to capture additional share in achondroplasia but to expand the treatable addressable market across a range of rare skeletal and genetic conditions…"

Read the full Bull Case to see why BioMarin Pharmaceutical could be undervalued

Bear case: 10% overvalued

"Heavy dependence on a few high-priced rare disease therapies and looming patent expirations expose BioMarin to regulatory, competitive, and pricing risks threatening long-term growth and profitability…"

Read the full Bear Case to see why BioMarin Pharmaceutical could be overvalued

Do you think there's more to the story for BioMarin Pharmaceutical? Head over to our Community to see what others are saying!

The Bottom Line

BioMarin Pharmaceutical screens as undervalued on market multiples, with the current P/S ratio below both industry and peer averages and also below the fair ratio estimate discussed earlier. The valuation case now turns on whether that discount reflects excess caution around execution and drug development or a genuine margin of safety. For you as an investor, the key question is whether BioMarin Pharmaceutical can translate its rare disease pipeline and the Alesta Therapeutics acquisition into durable revenue without the risks flagged in the bear case eroding that apparent discount.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com